Description
Maximize Confidence in Sensitive Molecular Applications with High-Quality DNA/RNA from Challenging FFPE Tissue Samples
The Maxwell® CSC XtractAll FFPE DNA/RNA Kit maximizes recovery of high-quality amplifiable DNA and RNA with high integrity from a variety of FFPE tissue types, including challenging samples. DNA and RNA are suitable for demanding downstream molecular applications such as NGS, digital PCR and more, supporting greater sensitivity and confidence in diagnostic and clinical research workflows.
High-yield and high-quality DNA and RNA extraction across diverse FFPE tissue types using the Maxwell® CSC XtractAll FFPE DNA/RNA Kit. DNA and RNA were extracted from a single section of each indicated FFPE human tissue type using either the Maxwell® CSC XtractAll FFPE DNA/RNA sequential workflow or two alternative manual kits following manufacturer protocols. DNA yield was assessed by qPCR targeting 150bp ( Panel A ) and 300bp ( Panel B ) amplicons. RNA yield was measured by RT-qPCR targeting 100bp ( Panel C ) and 171bp ( Panel D ) amplicons. Across all FFPE tissue types, the Maxwell® CSC XtractAll FFPE DNA/RNA Kit delivered comparable or higher DNA and RNA yields, particularly for longer amplicons, demonstrating its robust performance and effectiveness in recovering high-quality, amplifiable nucleic acids from challenging FFPE tissue samples. Data represent mean ± SD, N = 6.
Superior DNA and RNA fragment quality from FFPE tissue using the Maxwell® CSC XtractAll FFPE DNA/RNA Kit. DNA and RNA were extracted from single sections of a FFPE human breast tissue using the Maxwell® CSC XtractAll FFPE DNA/RNA sequential workflow and two other alternative FFPE DNA/RNA kits. Fragment quality was assessed using TapeStation analysis. Panel A. DNA fragment quality was assessed using the Agilent D5000 ScreenTape Assay. Panel B. RNA fragment quality and DV200 values were assessed using the Agilent RNA ScreenTape Assay. These results demonstrate that the Maxwell® CSC XtractAll FFPE DNA/RNA Kit yields high-quality, intact DNA and RNA with greater integrity compared to competitor kits, which show lower integrity and increased DNA and RNA fragmentation.
The high quality and amplifiability of DNA and RNA extracted from FFPE tissue samples obtained using the Maxwell® CSC XtractAll FFPE DNA/RNA Kit enables sensitive and reliable gene expression or mutational analysis in clinical and translational workflows.
Detection of oncogenic variants by digital PCR using RNA extracted from FFPE tissue. RNA was extracted from different FFPE human lung tumor tissue samples using the Maxwell® CSC XtractAll FFPE DNA/RNA sequential workflow and analyzed using a droplet digital PCR assay for EML4-ALK mRNA fusions. A representative 2D amplitude scatter plot displays the distinct cluster of droplets in the upper-left quadrant (in blue circle labeled as ‘Positive’), indicating successful amplification of the target gene fusion variant. Negative droplets are concentrated near the baseline, confirming strong signal separation and assay specificity.
DNA and RNA compatible with next-generation sequencing (NGS). DNA and RNA were extracted from a single section of FFPE human breast- and lung-tumor tissues using either the Maxwell® CSC XtractAll FFPE DNA/RNA sequential workflow (XtractAll) or a competitor FFPE DNA/RNA extraction kit (Competitor Q). Purified DNA and RNA samples were analyzed using the TruSight Oncology 500 (TSO 500) Assay (Illumina). Successful library preparation was achieved for all the samples, and sequencing was performed on the NovaSeq PE150 platform (Illumina), generating 80 million total reads per sample (40 million paired-end reads) at a coverage depth of 35,000X. Key quality control and NGS performance metrics for DNA and RNA extracted from the indicated FFPE tissue samples using the Maxwell® CSC XtractAll FFPE DNA/RNA Kit versus Competitor Q are presented. Compared to Competitor Q, the Maxwell® CSC XtractAll FFPE DNA/RNA Kit produced DNA and RNA with higher integrity and fragment length that exhibited better target coverage.
